Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
Holders of 5% or more of XLO
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Xilio Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 13G/A | 19.90%14.5M shares | 0.00 ppfrom 19.90% | Apr 5, 20244 filings | Feb 12, 2026 | SEC |
| Coastlands Capital LP | 13G | 9.99%5.35M shares | New | Dec 11, 20251 filing | Dec 11, 2025 | SEC |
| Coastlands Capital LP | 13G/A | 9.99%731.6K shares | – | Nov 13, 20261 filing | Nov 13, 2026 | SEC |
| Logos Global Management LP | 13G | 9.99%730.3K shares | New | Nov 16, 20261 filing | Nov 16, 2026 | SEC |
| Bain Capital Life Sciences Fund II, L.P. | 13G/A | 9.99%664.0K shares | – | May 15, 20261 filing | May 15, 2026 | SEC |
| OrbiMed Advisors LLC | 13G | 9.99%642.0K shares | New | May 15, 20261 filing | May 15, 2026 | SEC |
| Sirenia Capital Management LP | 13G | 9.90%1.14M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |
| StemPoint Capital LP | 13G/A | 9.50%628.9K shares | +1.10 ppfrom 8.40% | Nov 14, 20253 filings | Aug 14, 2026 | SEC |
| ADAR1 Capital Management, LLC | 13G | 9.30%381.0K shares | New | Nov 16, 20261 filing | Nov 16, 2026 | SEC |
| AbbVie Inc. | 13G | 9.00%4.35M shares | New | Feb 18, 20251 filing | Feb 18, 2025 | SEC |
| Bain Capital Life Sciences Fund II, L.P. | 13G/A | 8.50%6.26M shares | – | Nov 5, 20214 filings | Feb 17, 2026 | SEC |
| Adage Capital Management, L.P. | 13G | 7.06%464.6K shares | New | Nov 12, 20261 filing | Nov 12, 2026 | SEC |
| Frazier Life Sciences Public Fund, L.P. | 13G/A | 6.70%4.68M shares | −3.20 ppfrom 9.90% | Jun 12, 20253 filings | Feb 13, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
51 Schedule 13D and 13G filings on Xilio Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 16, 20269:56 PM ET | ADAR1 Capital Management, LLCand 1 other | 13G | 9.30%381.0K shares | New | Sep 30, 2025 | SEC |
| Nov 16, 20265:12 PM ET | Logos Global Management LPand 5 others | 13G | 9.99%730.3K shares | New | Jun 5, 2025 | SEC |
| Nov 13, 20269:22 PM ET | Coastlands Capital LPand 4 others | 13G/A | 9.99%731.6K shares | – | Sep 30, 2026 | SEC |
| Nov 12, 20269:01 AM ET | Adage Capital Management, L.P.and 2 others | 13G | 7.06%464.6K shares | New | Sep 30, 2026 | SEC |
| Aug 14, 202612:01 PM ET | StemPoint Capital LPand 2 others | 13G/A | 9.50%628.9K shares | +1.10 ppfrom 8.40% | Jun 30, 2026 | SEC |
| May 15, 20264:38 PM ET | OrbiMed Advisors LLCand 1 other | 13G | 9.99%642.0K shares | New | Mar 31, 2026 | SEC |
| May 15, 20264:30 PM ET | Bain Capital Life Sciences Fund II, L.P.and 2 others | 13G/A | 9.99%664.0K shares | – | Mar 31, 2026 | SEC |
| May 15, 20264:24 PM ET | Point72 Asset Management, L.P.and 2 others | 13G/A | 0.00%0 shares | −9.90 ppfrom 9.90%Below 5% | Mar 31, 2026 | SEC |
| May 15, 20268:06 AM ET | Sirenia Capital Management LPand 1 other | 13G | 9.90%1.14M shares | New | Mar 31, 2026 | SEC |
| Feb 17, 20264:30 PM ET | Bain Capital Life Sciences Fund II, L.P.and 3 others | 13G/A | 8.50%6.26M shares | – | Dec 31, 2025 | SEC |
| Feb 17, 202610:00 AM ET | StemPoint Capital LPand 2 others | 13G/A | 8.40%6.03M shares | +1.20 ppfrom 7.20% | Dec 31, 2025 | SEC |
| Feb 13, 20265:31 PM ET | Frazier Life Sciences Public Fund, L.P.and 13 others | 13G/A | 6.70%4.68M shares | −3.20 ppfrom 9.90% | Dec 31, 2025 | SEC |
| Feb 12, 20264:39 PM ET | Gilead Sciences, Inc. | 13G/A | 19.90%14.5M shares | 0.00 ppfrom 19.90% | Dec 31, 2025 | SEC |
| Dec 11, 20255:55 PM ET | Coastlands Capital LPand 4 others | 13G | 9.99%5.35M shares | New | Dec 4, 2025 | SEC |
| Nov 14, 20254:02 PM ET | Point72 Asset Management, L.P.and 2 others | 13G/A | 9.90%8.00M shares | +2.70 ppfrom 7.20% | Sep 30, 2025 | SEC |
| Nov 14, 202510:00 AM ET | StemPoint Capital LPand 2 others | 13G | 7.20%4.00M shares | New | Sep 30, 2025 | SEC |
| Aug 14, 20254:42 PM ET | Gilead Sciences, Inc. | 13G/A | 19.90%10.6M shares | 0.00 ppfrom 19.90% | Jun 30, 2025 | SEC |
| Aug 14, 20251:47 PM ET | Frazier Life Sciences Public Fund, L.P.and 19 others | 13G/A | 9.90%8.14M shares | 0.00 ppfrom 9.90% | Jun 30, 2025 | SEC |
| Jun 17, 20255:28 PM ET | Point72 Asset Management, L.P.and 2 others | 13G | 7.20%4.00M shares | New | Jun 5, 2025 | SEC |
| Jun 12, 20254:55 PM ET | Frazier Life Sciences Public Fund, L.P.and 19 others | 13G | 9.90%5.75M shares | New | Jun 5, 2025 | SEC |
| May 15, 202510:48 AM ET | Rock Springs Capital Management LPand 4 others | 13G/A | 0.00%0 shares | –Below 5% | Mar 31, 2025 | SEC |
| Feb 18, 20254:15 PM ET | AbbVie Inc. | 13G | 9.00%4.35M shares | New | Feb 11, 2025 | SEC |
| Dec 19, 20244:15 PM ET | Gilead Sciences, Inc. | 13G/A | 19.90%9.11M shares | – | Dec 18, 2024 | SEC |
| Nov 14, 2024 | Bain Capital Life Sciences Fund II, L.P. | 13G/AOld format | – | – | – | SEC |
| Nov 14, 2024 | Atlas Venture Fund XI, L.P. | 13G/AOld format | – | – | – | SEC |
| Nov 12, 2024 | Rock Springs Capital Management LP | 13G/AOld format | – | – | – | SEC |
| Nov 12, 2024 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Sep 27, 2024 | GKCC, LLC | 13GOld format | – | New | – | SEC |
| Jul 31, 2024 | Takeda Pharmaceutical Co Ltd | 13G/AOld format | – | – | – | SEC |
| Apr 5, 2024 | Gilead Sciences, Inc. | 13GOld format | – | New | – | SEC |
| Apr 5, 2024 | Rock Springs Capital Management LP | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Rock Springs Capital Management LP | 13GOld format | – | New | – | SEC |
| Feb 6, 2024 | Octagon Capital Advisors LP | 13G/AOld format | – | – | – | SEC |
| Feb 5, 2024 | Octagon Capital Advisors LP | 13G/AOld format | – | – | – | SEC |
| Apr 10, 2023 | MRL Ventures Fund LLC | 13GOld format | – | New | – | SEC |
| Feb 9, 2023 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Jan 25, 2023 | Octagon Capital Advisors LP | 13GOld format | – | New | – | SEC |
| Dec 29, 2022 | Flynn James E | 13G/AOld format | – | – | – | SEC |
| Nov 14, 2022 | Ra Capital Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Bain Capital Life Sciences Fund II, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Ra Capital Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | Flynn James E | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2022 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Jan 14, 2022 | Takeda Pharmaceutical Co Ltd | 13GOld format | – | New | – | SEC |
| Nov 5, 2021 | Atlas Venture Fund XI, L.P. | 13GOld format | – | New | – | SEC |
| Nov 5, 2021 | Bain Capital Life Sciences Fund II, L.P. | 13GOld format | – | New | – | SEC |
| Nov 5, 2021 | RiverVest Venture Fund IV, L.P. | 13DOld format | – | New | – | SEC |
| Nov 5, 2021 | Ra Capital Management, L.P. | 13GOld format | – | New | – | SEC |
| Nov 4, 2021 | FMR LLC | 13GOld format | – | New | – | SEC |
| Nov 3, 2021 | SV7 Impact Medicine Fund LP | 13DOld format | – | New | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Xilio Therapeutics, Inc. shares.
No Form 144 notices for Xilio Therapeutics, Inc. are on file.